Medicamentsen-ligne vous propose les traitements dont vous avez besoin afin de prendre soin de votre santé sexuelle. Avec plus de 5 ans d'expérience et plus de 80.000 clients francophones, nous étions la première clinique fournissant du acheter viagra original en France à vente en ligne et le premier vendeur en ligne de Cialis dans le monde. Pourquoi prendre des risques si vous pouvez être sûr avec Medicamentsen-ligne - Le service auquel vous pouvez faire confiance.

curriculum vitae

MARIANNE B. MÜLLER, M.D.
CURRICULUM VITAE
Max Planck Institute of Psychiatry Kraepelinstraße 10 80804 Munich Germany Phone: +49-89-30622-288 Fax:
Current Position: Head, Molecular Stress Physiology Group, MPI of Psychiatry
EDUCATION


1987-1989

Student at the Rheinische Hochschule für Musik Köln (Cologne University of Music), instrumental music performance, piano
1989-1995
Medical Degree (german state examination) Department of Neuropathology, University of Bonn (Prof. Dr. O.D. Wiestler) PROFESSIONAL EXPERIENCE AND EMPLOYMENT
1/96-7/96
Junior research scientist, Molecular Neuro-Oncology, Dep. of Neuropathology, University of Bonn (Prof. Dr. O.D. Wiestler)
since 7/96
Fellowship at the Max Planck Institute of Psychiatry, Munich, Resident in Psychiatry (full-time clinical work)
4/97 - 6/97
Visiting scientist at the Netherlands Institute for Brain Research, Amsterdam (Prof. Dr. D. F. Swaab)
7/97-3/99

Resident in Psychiatry, Max Planck Institute of Psychiatry, Munich
4/99-5/2001

Full-time preclinical research in the Molecular Neurogenetics Group (Prof. W. Wurst), Max Planck Institute of Psychiatry 06/01-05/03
Resident in Psychiatry and Neurology, Max Planck Institute of Psychiatry, Munich
06/03-12/03

Full-time preclinical research in the Molecular Neurogenetics Group (Prof. W. Wurst), Max Planck Institute of Psychiatry Speciality board: Psychiatry and Psychotherapy (Facharzt)
since 01/04
Group leader of the „Molecular Stress Physiology“ research group at the Max Planck Institute of Psychiatry
02/04-11/06
Assistant Medical Director (open psychiatric ward)
since 08/04

W2-Professorship award for outstanding women in science from the Max Planck Society for the Advancement of Sciences Habilitation at the Ludwig-Maximilians-University, Munich (postdoctoral lecture qualification in psychiatry to qualify for professor positions in Germany)
CLINICAL FOCUS
Treatment-resistant depression
Anxiety disorders
FELLOWSHIPS AND HONORS

1990-1995
Fellow of the Studienstiftung des Deutschen Volkes (German National Academic Foundation)
7/97-7/99
Fellowship from the Max Planck Society for the Advancement of Science Poster Award, 13th Congress of the European College of Neuropsychopharmacology Robert-Sauer Award (Bavarian Academy of Sciences and Humanities)
GRANTS

01/2000 – 2004
BMBF Federal Ministry of Education, Science, Research and Technology. Member MedNet “Depression and Suicidality” Bayerischer Habilitations-Förderpreis (thesis award and 3-years research grant for obtaining a postdoctoral degree to qualify for professor positions in Germany; total: 150.000 € )
02/2008-04/2011
European Union /Seventh Framework Program: Collaborative grant Synaptic mechanisms of memory loss: novel cell adhesion molecules as therapeutic targets Work package leader and Principle Investigator
PUBLICATIONS

Overall, I have published more than 70 scientific papers in international peer-reviewed
scientific journals. The average citation rate per publication is 35.2 and the Hirsch index is 27 (Web of knowledge, search for author Müller MB* OR Mueller MB* OR Muller MB*).
Schmidt MV, Schülke J-P, Liebl C, Stiess M, Avrabos C, Bock J, Wochnik GM, Davies HA,
Zimmermann N, Scharf SH, Trümbach D, Wurst W, Zieglgänsberger W, Turck C, Holsboer F,
Stewart MG, Bradke F, Eder M, Müller MB*, Rein T* (2011). The tumor suppressor DRR1 is a
stress-induced actin bundling factor that modulates synaptic efficacy and cognition.
Proceedings of the National Academy of Science (in press)
*shared last authorship
Scharf SH, Liebl C, Binder EB, Schmidt MV, Müller MB (2011). Expression and regulation of
the fkbp5 gene in the adult mouse brain. PLoS One
doi:10.1371/journal.pone.0016883
Hartmann J, Wagner KV, Liebl C, Scharf SH, Wang XD, Wolf M, Hausch F, Rein T, Schmidt U,
Touma C, Cheung-Flynn J, Cox MB, Smith DF, Holsboer F, Müller MB, Schmidt MV (2011).
The involvement of FK506-binding protein 51 (FKBP5) in the behavioral and neuroendocrine
effects of chronic social defeat stress.
Neuropharmacology
Wagner KV, Wang XD, Liebl C, Scharf SH, Müller MB, Schmidt MV (2011). Pituitary
glucocorticoid receptor deletion reduces vulnerability to chronic stress
Psychoneuroendocrinology 36: 579-587
Kohli, MA, Lucae S, Sämann PG, Schmidt MV, Demirkan A, Hek K, Roeske D, Alexander M,
Salyakina D, Ripke S, Höhn D, Specht M, Menke A, Hennings J, Heck A, Wolf C, Ising M,
Schreiber S, Czisch M, Müller MB, Uhr M, Bettecken T, Beckers A, Schramm J, Rietschel M,
Maier W, Bradley B, Ressler KJ, Nöthen MM, Cichon S, Craig IW, Breen G, Lewis CM, Hofman
A, Tiemeier H, van Duijn CM, Holsboer F, Müller-Myhsok B, Binder EB (2011). The neuronal
transporter gene SLC6A15 confers risk to major depression. Neuron 70: 252-265
Wang XD, Chen Y, Wolf M, Wagner KV, Liebl C, Scharf SH, Harbich D, Mayer B, Wurst W,
Holsboer F, Deussing JM, Baram TZ, Müller MB, and Schmidt MV (2011). Forebrain CRHR1
Deficiency Attenuates Chronic Stress-Induced Cognitive Deficits and Dendritic Remodeling.
Neurobiology of Disease 42: 300-310
Wang XD, Rammes G, Kraev I, Wolf M, Liebl C,, Scharf SH, Rice C, Wurst W, Holsboer F,
Deussing J, Baram TZ, Stewart M, Müller MB, Schmidt MV (2011). Forebrain CRF1 modulates
early life stress-programmed cognitive deficits. The Journal of Neuroscience (in press)
Schmidt MV, Trümbach D, Weber P, Wagner K, Scharf SH, Liebl C, Datson N, Namendorf C,
Gerlach T, Kühne C, Uhr M, Deussing JM, Wurst W, Binder EB, Holsboer F, Müller MB (2010).
Individual stress vulnerability is predicted by short-term memory and AMPA receptor subunit
ratio in the hippocampus. The Journal of Neuroscience 30:16949-16958
Schmidt MV, Scharf SH, Liebl C, Harbich D, Mayer B, Holsboer F, Müller MB (2010). A novel
chronic stress paradigm in female mice. Hormones and Behavior 57(4-5):415-20
Schmidt MV, Scharf SH, Sterlemann V, Ganea K, Liebl C, Holsboer F and Müller MB (2010)
High susceptibility to chronic social stress is associated with a depression-like phenotype.
Psychoneuroendocrinology
35 :635-43

Sterlemann V, Rammes G, Liebl C, Ganea K, Müller MB* and Schmidt MV* (2010). Cognitive
impairment in aged mice following chronic social stress during adolescence; Hippocampus
20(4):540-9
*shared last authorship

Thöringer CK, Erhardt A, SIllaber I, Müller MB, Ohl F, Holsboer F, Keck ME (2010). Long-term
anxiolytic and antidepressant-like behavioural effects of tiagabine, a selective GABA
transporter-1 (GAT-1) inhibitor, coincide with a decrease in HPA system activity in C57BL/6
mice. Journal of Psychopharmacology 24: 733-743

Schmidt MV, Sterlemann V, Wagner K, Niederleitner B, Ganea K, Liebl C, Deussing JM, Berger
S, Schütz G, Holsboer F, Müller MB (2009). Postnatal glucocorticoid excess due to pituitary
glucocorticoid receptor deficiency: differential short- and long-term consequences.
Endocrinology 150: 2709-2716

Schmidt MV, Czisch M, Sterlemann V, Reinel C, Sämann P, Müller MB (2009). Chronic social
stress during adolescence in mice alters fat distribution in late life: Prevention by antidepressant
treatment. Stress 12: 89-94

Greetfeld M , Schmidt MV, Ganea K, Sterlemann V, Liebl C, Müller MB (2009). A single
episode of restraint stress regulates central corticotrophin-releasing hormone receptor
expression and binding in specific areas of the mouse brain. Journal of Neuroendocrinology
21: 473-480
Liebl C, Panhuysen M, Pütz B, Trümbach D, Wurst W, Deussing JM, Schmidt MV and Müller
MB
(2009). Gene expression profiling following maternal deprivation: involvement of the brain
renin-angiotensin system. Frontiers in Molecular Neuroscience 2009; published online, DOI:
10.3389/neuro.02.001.2009
Erhardt A, Müller MB, Rödel A, Welt T, Ohl F, Holsboer F, Keck ME (2009). Consequences of
chronic social stress on behaviour and vasopressin gene expression in the PVN of
DBA/2OlaHsd mice – influence of treatment with the CRHR1-receptor antagonist R121919/NBI
30775. Journal of Psychopharmacology 23, 31-39

Sterlemann V, Ganea K, Liebl C, Harbich D, Alam S, Holsboer F, , Schmidt MV, Müller MB
(2008). Long-term behavioural and neuroendocrine alterations following chronic social stress in
mice: implications for stress-related disorders. Hormones and Behavior 53: 386-394
Keck ME, Kern N, Erhardt A, Unschuld PG, Ising M, Salyakina D, Müller MB, Knorr CC, Lieb R,
Hohoff C, Krakowitzky P, Maier W, Bandelow B, Fritze J, Deckert J, Holsboer F, Müller-Myhsok
B, Binder EB (2008). Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes
in a case/control study for panic disorder. American Journal of Medical Genetics Part B;
147B: 1196-1204.

Schmidt MV, Liebl C, Sterlemann V, Ganea K, Hartmann J, Harbich D, Alam S, Müller MB
(2008) Neuropeptide Y mediates the initial hypothalamic–pituitary–adrenal response to maternal
separation in the neonatal mouse. Journal of Endocrinology 197: 421-427
Schmidt MV, Oitzl MS, Steenbergen P, Lachize S, Wurst W, Müller MB, de Kloet ER and Meijer
OC (2007) Ontogeny of steroid receptor coactivators in the hippocampus and their role in
regulating postnatal HPA axis function. Brain Research 1174: 1-6
Thöringer CK, Sillaber I, Rödel A, Erhardt A, Müller MB, Ohl F, Holsboer F, Keck ME (2007).
Temporal dynamics of intrahippocampal corticosterone in response to stress-related stimuli with
different emotional and physical load: an in vivo microdialysis study in C57/BL6 and DBA/2
inbred mice. Psychoneuroendocrinology 32: 746-757
Thöringer CK, Binder EB, Salyakina D, Erhardt A, Ising M, Unschuld PG, Kern N, Lucae S,
Brückl TM, Müller MB, Fuchs B, Pütz B, Lieb R, Uhr M, Holsboer F, Müller-Myhsok B, Keck ME
(2007).
Association of a Met88Val diazepam binding inhibitor (DBI) gene polymorphism and anxiety
disorders with panic attacks. Journal of Psychiatric Research 41: 579-584
Ganea K, Liebl C, Sterlemann V, Müller MB, Schmidt MV (2007). Pharmacological validation of
a novel home cage activity counter in mice. Journal of Neuroscience Methods 162: 180-186
Schmidt MV, Sterlemann V, Ganea K, Alam S, Harbich D, Greetfeld M, Uhr M, Holsboer F,
Müller MB (2007). Persistent neuroendocrine and behavioral effects of a novel, etiologically
relevant mouse paradigm for chronic social stress during adolescence
Psychoneuroendocrinology 32: 417-429
Müller MB and Holsboer F (2006). Mice with mutations in the HPA-System as models for
symptoms of depression. Biological Psychiatry 59: 1104-1115
Lucassen PJ, Heine VM, Müller MB, van der Beek EM, Wiegant VM, de Kloet ER, Joels M,
Fuchs E, Swaab DF, Czeh B (2006). Stress, depression and hippocampal apoptosis. CNS &
Neurological Disorders – Drug Targets
5: 531-546
Schmidt MV and Müller MB (2006). Animal models of anxiety. Drug discovery today. Disease
Models
3: 369-374
Ngyen, NK, Keck ME, Hetzenauser, Thöringer CK, Wurst W, Deussing JM, Holsboer F, Müller
MB
, Singewald N (2006). Conditional CRF receptor knockout mice show altered neuronal
activation pattern to mild anxiogenic challenge. Pysychopharmacology 188: 374-385
Schmidt MV, Levine S, Alam S, Harbich D, Sterlemann V, Ganea K, de Kloet ER, Holsboer F,
Müller MB (2006). Metabolic signals modulate hypothalamic-pituitary-adrenal axis activation
during maternal separation of the neonatal mouse. Journal of Neuroendocrinology 18: 865-
874
Schmidt MV, Deussing JM, Oitzl MS, Ohl F, Levine S, Wurst W, Holsboer F, Müller MB, de
Kloet ER (2006). Differential disinhibition of the neonatal hypothalamic-pituitary-adrenal axis in
brain specific CRH receptor 1 knockout mice. European Journal of Neuroscience 24: 2291-
2298
Welt T, Engelmann M, Renner U, Erhardt A, Müller MB, Holsboer F, Landgraf R, Keck ME
(2006). Temazepam triggers the release of vasopressin into the rat hypothalamic
paraventricular nucleus: novel insights into benzodiazepine action on hypothalamic-pituitary-
adrenocortical system activity during stress. Neuropsychopharmacology 31: 2573-2579
Refojo D, Echenique C, Müller MB, Reul JMHM, Deussing JM, Wurst W, Sillaber I, Paez-
Pereda M, Holsboer F, Arzt E (2005). CRH activates ERK1/2 MAPK in specific brain areas.
Proceedings of the National Academy of Sciences
102: 6183-6188
Keck ME, Ohl F, Holsboer F, Müller MB (2005). Listening to mutant mice: a spotlight on the role
of CRH/CRH receptor systems in affective disorders. Neuroscience & Biobehavioral Reviews
29: 867-889
Schmidt M, Levine S, Oitzl MS, van der Mark M, Müller MB, Holsboer F, de Kloet ER (2005).
Glucocorticoid receptor blockade disinhibits pituitary-adrenal activity during the stress hypo-
responsive period of the mouse: role of maternal signals. Endocrinology 146: 1458-1464
Keck ME, Sartori SB, Welt T, Müller MB, Ohl F, Holsboer F, Landgraf R, Singewald N (2005).
Differences in serotonergic neurotransmission between rats displaying high or low
anxiety/depression-like behavior: effects of chronic paroxetine treatment. Journal of
Neurochemistry
92: 1170-1179
Erhardt A, Sillaber I, Welt T, Müller MB, Singewald N, Keck ME (2004). Repetitive Transcranial
Magnetic Stimulation Increases the Release of Dopamine in the Nucleus Accumbens Shell of
Morphine-Sensitized Rats During Abstinence. Neuropsychopharmacology 29: 2074 – 2080
Müller MB and Wurst W (2004). Getting closer to affective disorders: the role of CRH receptor
systems. Trends in Molecular Medicine 10: 409-415
Keck ME, Holsboer F, Müller MB (2004). Mouse mutants for the study of corticotropin-releasing
hormone receptor function: Development of novel treatment strategies for mood disorders
Annals of the New York Academy of Sciences 1018: 445-457
Müller MB, Uhr M, Holsboer F, Keck ME (2004). Hypothalamic-pituitary-adrenocortical system
and mood disorders: highlights from mutant mice. Neuroendocrinology 79: 2-13
Keck ME, Müller MB, Binder EB, Sonntag A, Holsboer (2004). Ziprasidone-related tardive
dyskinesia. American Journal of Psychiatry 161: 175-176
Müller MB, Zimmermann S, Sillaber I, Hagemeyer TP, Timpl P, Kormann MSD, Droste S,
Deussing JM, Kühn R, Reul JMHM, Holsboer F, Wurst W (2003). Limbic corticotropin-releasing
hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress.
Nature Neuroscience 6: 1100-1107
Müller MB, Keck ME, Binder EB, Kresse AE, Hagemeyer TP, Landgraf R, Holsboer F, Uhr M
(2003). ABCB1 (MDR1)-type P-glycoproteins at the blood-brain barrier modulate the activity of
the hypothalamic-pituitary-adrenocortical system: implications for affective disorder.
Neuropsychopharmacology 28: 1991-1999
Keck ME, Welt T, Müller MB, Landgraf R, Holsboer F (2003). The high-affinity non-peptide
CRH1 receptor antagonist R121919 attenuates stress-induced alterations in plasma oxytocin,
prolactin and testosterone secretion. Pharmacopsychiatry 36: 27-31
Keck ME, Welt T, Erhardt A, Müller MB, Sillaber I (2003). Neuroendocrinological changes
induced by transcranical magnetic stimulation (rTMS) – a focus on dopamine and vasopressin.
Nervenheilkunde 22: 346-349
Keck ME, Welt T, Müller MB, Uhr M, Ohl F, Wigger A, Toschi N, Holsboer F, Landgraf R
(2003). Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant
behavioral effects of chronic paroxetine treatment in a psychopathological rat model.
Neuropsychopharmacology 28: 235-243
Schmidt M, Oitzl MS, Müller MB, Ohl F, Wurst W, Holsboer F, Levine S, de Kloet ER (2003).
Regulation of the developing hypothalamic-pituitary-adrenal axis in CRH receptor 1 deficient
mice. Neuroscience 119: 589-595
Droste SK, Gesing A, Ulbricht S, Müller MB, Linthorst ACE, Reul JMHM (2003). Effects of long-
term voluntary exercise on the mouse hypothalamic-pituitary-adrenocortical axis.
Endocrinology 144: 3012-3023
Keck ME, Wigger A, Welt T, Müller MB, Gesing A, Reul JMHM, Holsboer F, Landgraf R,
Neumann ID (2002). Vasopressin mediates the response of the combined dexamethasone/CRH
test in hyper-anxious rats: implications for pathogenesis of affective disorders.
Neurospychopharmacology 26: 94-105
Müller MB und Keck ME (2002) Genetically engineered mice for studies of stress-related
clinical conditions. Journal of Psychiatric Research 36: 53-76

Müller MB,
Holsboer F, Keck ME (2002). Genetic modification of corticosteroid receptor
signalling: novel insights into pathophysiology and treatment strategies of human affective
disorders. Neuropeptides 36: 117-131
Czéh B, Welt T, Fischer A, Erhardt A, Schmitt W, Müller MB, Toschi N, Fuchs E, Keck ME
(2002). Chronic psychosocial stress and concomitant repetitive transcranial magnetic
stimulation: effects on stress hormone levels and adult hippocampal neurogenesis. Biological
Psychiatry
52: 1057-1065
Uhr M, Holsboer F, Müller MB (2002). Penetration of endogenous steroid hormones
corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice
deficient for both mdr1a and mdr1b P-glycoproteins. Journal of Neuroendocrinology 2002;
14: 753-759
Keck ME, Erhard A, Müller MB, Erhardt A, Ohl F, Toschi N, Holsboer F, Sillaber I (2002).
Repetitive transcranial magnetic stimulation increases the release of dopamine in the
mesolimbic and neostriatal system. Neuropharmacology 43: 101-109

Müller MB, Preil J, Renner U, Zimmermann S, Kresse AE, Stalla GK, Keck ME, Holsboer F,
Wurst W (2001). Expression of CRHR1 and CRHR2 in mouse pituitary and adrenal gland:
implications for HPA system regulation. Endocrinology 142: 4150-5153
Müller MB, Lucassen P, Yassouridis A, Hoogendijk WGJ, Holsboer F, Swaab DF (2001).
Neither major depression nor glucocorticoid treatment affects the cellular integrity of the human
hippocampus. European Journal of Neuroscience 14: 1603-1612
Preil J#, Müller MB#, Gesing A, Reul JMHM, Sillaber I, van Gaalen M, Landgrebe J, Stenzel-
Poore M, Holsboer F, Wurst W (2001). Regulation of the hypothalamic-pituitary-adrenocortical
system in mice deficient for CRH receptors 1 and 2. Endocrinology 142: 4946-4955
(# shared first authorship)
Lucassen PJ, Müller MB, Holsboer F, Bauer J, Holtrop A, Wouda A, de Kloet ER, Swaab DF
(2001). Hippocampal apoptosis in major depression is a minor event and absent from subareas
of risk for glucocorticoid exposure. American Journal of Pathology 158: 453-468
Keck ME, Welt T, Post A, Müller MB, Toschi N, Wigger A, Landgraf R, Holsboer F, Engelmann
M (2001). Neuroendocrine and behavioral effects of repetitive transcranial magnetic stimulation
in a psychopathological animal model are suggestive of antidepressant-like effects.
Neuropsychopharmacology 24: 337-349
Müller MB, Landgraf R, Keck ME (2000). Vasopressin, major depression and hypothalamic-
pituitary-adrenocortical desensitization. Biological Psychiatry 48: 330-333
Müller MB, Toschi N, Kresse A, Post, A, Keck ME (2000). Long-term repetitive transcranial
magnetic stimulation increases the expression of brain-derived neurotrophic factor and
cholecystokinin mRNA, but not neuropeptide tyrosine mRNA in specific areas of rat brain.
Neuropsychopharmacology 23: 205-215
Müller MB, Landgraf R, Preil J, Zimmermann S, Sillaber I, Kresse AE, Keck ME, Holsboer F,
Wurst W (2000). Selective activation of the hypothalamic vasopressinergic system in mice
deficient for the corticotropin-releasing hormone receptor 1 is dependent on glucocorticoids.
Endocrinology 141: 4262-4269
Müller MB, Keck ME, Zimmermann, S, Holsboer F, Wurst W (2000). Disruption of feeding
behavior in CRH receptor 1-deficient mice is dependent on glucocorticoids. NeuroReport 11:
1963-1966
Chen Y, Brunson K, Müller MB, Cariaga W, Baram TZ (2000). Immunocytochemical distribution
of corticotropin-releasing hormone type-1 (CRF1)-like immunoreactivity in the mouse brain: light
microscopy analysis using an antibody directed against the C-terminus. Journal of
Comparative Neurolog
420: 305-323
Keck ME, Engelmann M, Müller MB, Henniger MSH, Toschi N, Hermann B, Rupprecht R,
Neumann ID, Landgraf R, Post A (2000). Repetitive transcranial magnetic stimulation induces
active coping strategies and attenuates the neuroendocrine stress response in rats. Journal of
Psychiatric Research
34: 265-276
Müller MB, Schmidt M, Hayashi Y, Rollbrocker B, Waha A, Fimmers R, Volk B, Warnke P,
Ostertag CB, Wiestler OD, von Deimling A (1999). Molecular genetic analysis as a tool for
evaluating stereotactic biopsies of glioma specimens. Journal of Neuropathology and
Experimental Neurology
58: 40-44
Post A, Müller MB, Engelmann M, Keck ME (1999). Repetitive transcranial magnetic
stimulation in rats – evidence for a neuroprotective effect in vitro and in vivo. European Journal
of Neuroscience
11: 3247-3254
Ströhle A, Müller MB, Rupprecht R (1998). Marijuana precipitation of panic disorder with
agoraphobia. Acta Psychiatrica Scandinavica 96: 254-255

Wolf HK, Wellmer J, Müller MB, Wiestler OD, Hufnagel A, Pietsch T (1995). Glioneuronal
malformative lesions and dysembryoplastic neuroepithelial tumors in patients with chronic
pharmacoresistant epilepsies. Journal of Neuropathology and Experimental Neurology 54:
245-254

Wolf HK, Müller MB, Spänle M, Zentner J, Schramm J, Wiestler OD (1994). Ganglioglioma: A
detailed histopathological and immunohistochemical analysis of 61 cases. Acta
Neuropathologica
88: 166-173
Wolf HK, Spänle M, Müller MB, Elger CE, Schramm J, Wiestler OD (1994). Hippocampal loss
of the GABA-A receptor 1 subunit in patients with chronic pharmacoresistant epilepsies. Acta
Neuropathologica
88: 313-321

Source: http://www.mpipsykl.mpg.de/en/research/groups/mueller_m/misc/cv_mueller_m.pdf

Microsoft word - intelrev.tv press release - sept 18th 2013.docx

IntellectualRevolution.tv Proudly Announces Launch of Free Educational Discovery Website: An Online Resource Focused on Personal Growth and Global Evolutionary Challenges. Educate – Enlighten – Empower – Engage – Evolve LOS ANGELES, Sept 18th, 2013. Throughout history, all human progress can be linked to knowledge. With the proliferation of knowledge that is on the Internet, we

Untitled

Alizyme plc Interim Report 2004 ALIZYME plc | Interim Report 2004 Highlights ■ Revenues of £1.6 million (H1 2003: Nil) ■ Loss after tax £1.0 million (H1 2003: £7.1 million) ■ Cash and short term investments at 30 June 2004 of £20.6 million (2003: £15.4 million) ■ Renzapride (Irritable Bowel Syndrome) Successful clinical trial in c-IBS patients at Mayo Clinic, US

Copyright © 2010-2014 Pharmacy Pills Pdf